Halozyme Therapeutics revenue and financials

HALO · NASDAQ · USD

$109.72+1.30%+$1.41

Close · October 6, 2026

In the fiscal year ended December 2025, Halozyme Therapeutics reported revenue of $1.4B (+37.55% year over year). Net income was $316.89M, a net margin of 22.7%.

Annual revenue · 2025: $1.4B

$146.69M2016
$316.61M2017
$151.86M2018
$195.99M2019
$267.59M2020
$443.31M2021
$660.12M2022
$829.25M2023
$1.02B2024
$1.4B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +37.55%; 2025 vs 2024
Net income growth: −28.64%; 2025 vs 2024
Net margin: 22.7%; 2024: 43.7%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total revenue	481	377	452	354	326	265	298	290	231	196	230	216
Cost of revenue	107	105	111	72.5	63.9	63.2	62.5	67.9	60.6	47.4	73.6	72.1
Gross profit	374	272	341	282	262	202	236	222	171	148	156	144
Selling, general and administrative	57.0	57.9	63.3	46.1	41.6	42.4	42.2	41.2	35.7	35.1	37.6	35.3
Research and development	27.7	25.6	31.9	17.3	17.5	—	—	—	—	—	—	—
Operating income	288	185	254	218	202	142	176	163	117	95.5	101	90.8
EBIT	288	185	254	218	202	142	176	163	117	95.5	101	90.8
EBITDA	319	216	279	237	221	160	195	182	136	114	120	110
Interest expense	5.6	5.5	4.9	4.3	4.4	4.5	4.5	4.5	4.5	4.5	5.2	4.5
Pre-tax income	285	180	-101	219	205	144	178	165	118	96.0	101	102
Income tax	55.0	30.3	40.7	43.7	39.8	25.7	41.2	28.1	24.5	19.2	15.8	19.9
Net income	230	150	-142	175	165	118	137	137	93.2	76.8	85.4	81.8
Net income to common shareholders	230	150	-142	175	165	118	137	137	93.2	76.8	85.4	81.8
Basic EPS	1.96	1.27	-1.20	1.49	1.36	0.96	1.08	1.08	0.73	0.61	0.66	0.62
Diluted EPS	1.90	1.22	-1.20	1.43	1.33	0.93	1.06	1.05	0.72	0.60	0.65	0.61
Average shares (basic)	117	118	118	117	121	123	126	127	127	127	129	132
Average shares (diluted)	121	123	118	122	124	127	129	130	129	129	131	134